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Abstract
Purpose The aim of the study was to investigate DNA double
strand break (DSB) formation and its correlation with the
absorbed dose to the blood lymphocytes of patients undergo-
ing their first peptide receptor radionuclide therapy (PRRT)
with 177Lu-labelled DOTATATE/DOTATOC.
Methods The study group comprised 16 patients receiving
their first PRRT. At least six peripheral blood samples were
obtained before, and between 0.5 h and 48 h after radionuclide
administration. From the time–activity curves of the blood and
the whole body, residence times for blood self-irradiation and
whole-body irradiation were determined. Peripheral blood
lymphocytes were isolated, fixed with ethanol and subjected
to immunofluorescence staining for colocalizing γ-H2AX/
53BP1 DSB-marking foci. The average number of DSB foci
per cell per patient sample was determined as a function of the
absorbed dose to the blood and compared with an in vitro
calibration curve established in our laboratory with 131I and
177Lu.
Results The average number of radiation-induced foci (RIF)
per cell increased over the first 5 h after radionuclide admin-
istration and decreased thereafter. A linear fit from 0 to 5 h as a
function of the absorbed dose to the blood agreed with our
in vitro calibration curve. At later time-points the number of
RIF decreased, indicating progression of DNA repair.
Conclusion Measurements of RIF and the absorbed dose to
the blood after systemic administration of 177Lu may be used
to obtain data on the individual dose–response relationships
in vivo. Individual patient data were characterized by a linear
dose-dependent increase and an exponential decay function
describing repair.
Keywords γ-H2AX .53BP1 .Biologicaldosimetry .Peptide
receptor radionuclide therapy . Absorbed dose to blood . DSB
focus assay . DNA damage . 177Lu . Ionizing radiation
Introduction
Patients who develop neuroendocrine and other tumour enti-
ties overexpressing peptide receptors can be treated with pep-
tide receptor radionuclide therapy (PRRT) leading to longer
survival and improved quality of life [1]. This molecular
targeted radiation therapy involves the systemic administra-
tion of a radiolabelled peptide designed to target the
overexpressed receptors on tumour cells with high affinity
and specificity [1]. In the past 15 years, PRRT with the
radiolabelled somatostatin receptor agonists 90Y-DOTA-D-
Phe-Tyr3-octreotide (90Y-DOTATOC), 177Lu-DOTA-D-Phe-
Tyr3-octreotate (177Lu-DOTATATE) and 177Lu-DOTA-D-
Phe-Tyr3-octreotide (177Lu-DOTATOC) have been success-
fully used to target metastatic and inoperable neuroendocrine
tumours (NET) expressing somatostatin receptor subtype 2
[1–3]. PRRT has also been used to treat meningioma [4–7]
and thyroid cancer [8–10].
The haematological toxicity of this treatment is an issue,
since it has been observed particularly after the administration
Harry Scherthan and Michael Lassmann share senior authorship.
Electronic supplementary material The online version of this article
(doi:10.1007/s00259-015-3083-9) contains supplementary material,
which is available to authorized users.
* Uta Eberlein
eberlein_u@klinik.uni-wuerzburg.de
1 Department of Nuclear Medicine, University of Würzburg,
Oberdürrbacher Str. 6, 97080 Würzburg, Germany
2 Bundeswehr Institute of Radiobiology affiliated to the University of
Ulm, 80937 Munich, Germany
Eur J Nucl Med Mol Imaging (2015) 42:1739–1749
DOI 10.1007/s00259-015-3083-9
of 90Y-labelled DOTA compounds [11], whereas treatment
with 177Lu-labelled compounds delivers lower absorbed doses
to the bone marrow [12]. In agreement with this, patients
receiving 177Lu-DOTATATE/DOTATOC did not show hae-
matological toxicity with the exception of one with grade 3
leukopenia and thrombocytopenia [13]. In any case, systemic
administration of therapeutic radionuclide activities will lead
to DNA damage because of the protracted whole-body
irradiation.
PRRT also provides the opportunity to study the effects of
prolonged systemic β- and γ-irradiation after administration
of 177Lu in vivo. In this setting, all organs including the blood
are irradiated by β-particles emitted from circulating 177Lu
and from penetrating γ-radiation originating from activity dis-
persed throughout the body. The absorbed dose and dose rate
to the blood after systemic administration of 177Lu-labelled
compounds is assessed by defining the time–activity curves
in the blood and the whole body, integrating the correspond-
ing time–activity curves and calculating the absorbed dose
[14].
Furthermore, radiation exposure can be correlated with bio-
logical effects, including DNA damage that is assessed
biodosimetrically in terms of chromosome aberrations or
DNA double strand breaks (DSBs). DSBs are critical cellular
lesions that can result from genotoxins such as ionizing radia-
tion or chemical compounds [15–17]. Their formation in nu-
clear chromatin results in rapid phosphorylation of the histone
H2 variant H2AX, called γ-H2AX [15, 18, 19]. DSBs also
recruit the damage sensor 53BP1 to the chromatin surrounding
the DSBs [20–24], which leads to 53BP1 and γ-H2AX
colocalization in the chromatin surrounding a DSB [20, 22,
25–27]. Therefore, radiation-induced DSBs can be addressed
by microscopically visible DNA damage protein foci that dis-
play bothγ-H2AX and 53BP1 immunofluorescence [27].With
progression of DSB repair, γ-H2AX and 53BP1 foci disappear
[28]. The immunofluorescence staining for colocalizing γ-
H2AX/ 53BP1 foci and their quantification as DSBs has been
termed the DNA damage focus assay [26, 27].
At present, there are only two studies that have quantified
radiation-induced DNA damage focus formation after treat-
ment of differentiated thyroid cancer (DTC) with the isotope
131I, either using radiation-induced colocalizing γ-H2AX and
53BP1 foci [29] or γ-H2AX foci only [30]. A more recent
study has addressed γ-H2AX foci formation after 177Lu ther-
apy of NET [31]. In these studies elevated levels of radiation-
induced DNA damage foci were observed after treatment, but
a dose–response relationship could not be established.
The aims of the present study were therefore, (a) to estab-
lish a methodology for describing absorbed doses to the blood
in patients after PRRT similar to the formalism developed for
radioiodine therapy of thyroid cancer [32], (b) to describe the
temporal and dose-dependent behaviour of the DNA damage
focus assay in radiation treatment-naive patients after their
first PRRT with 177Lu, (c) to compare the in vivo dose re-
sponse in the first hours after therapy with an in vitro calibra-
tion curve established recently in our laboratory [27], and (d)
to describe and quantify the decay of foci at later time-points
after administration of the radiopharmaceutical as a potential
measure of the repair of radiation-induced double stranded
DNA damage in vivo.
Materials and methods
Research design and subjects
Patients referred to our centre for initial treatment with 177Lu-
labelled DOTATATE/DOTATOC were included in this study.
The treatment was done on a compassionate use basis in pa-
tients with an advanced stage of their disease or who were
without any other therapeutic options. Haematological disease
was an exclusion criterion. During the week prior to treatment
with radiolabelled peptides patients were requested not to re-
ceive ionizing radiation for diagnosis and/or treatment.
Before PRRT, patients were hospitalized in our ward to
check their medical condition. On the treatment day, a mixture
of L-arginine and L-lysine was given immediately before
PRRT over 3.5 to 4 h to reduce the dose to the kidneys [1].
The 177Lu-labelled DOTATATE/TOC activity was then deliv-
ered using a perfusion system over a period of 20 min. The
end of the administration process was chosen as the starting
point of the study. After the start of treatment the patients
stayed in our ward for 2 days.
Blood sampling and activity determination in blood
samples
Blood samples were drawn in all patients prior to administration
and nominally at 1, 2, 3, 4, 24 and 48 h after administration
using Li-heparin blood collecting tubes (S-Monovette, Sarstedt,
Germany). For exact quantification of the blood activity concen-
tration, an aliquot of 0.1 mL of each heparinized blood sample
was measured in a well counter (Canberra, Germany) or in a
high-purity germanium detector (Canberra, Germany). The
counting efficiencies of the detectors were determined by repeat-
ed measurements of a NIST-traceable standard. The measured
values were decay-corrected to the time of blood sampling.
Blood sample preparation for the DNA damage focus
assay
Separation and fixation of white blood cells and counting of
the foci followed the protocol described by Eberlein et al. [27]
the foci being stained according to the procedure described by
Lassmann et al. [29] and Lamkowski et al. [26]. The average
numbers of radiation-induced damage foci (RIF) per cell were
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obtained by subtracting the background number of foci for
each counted sample. A detailed description of this method
is provided in the Supplementary material.
Measurement of the whole-body retention
Whole-body activity retention was determined in all patients
by combining external dose rate measurements and whole-
body gamma camera scans. For the first measurement, the
patients were asked not to micturate or defaecate after admin-
istration of the radiopharmaceutical. Prior to subsequent mea-
surements they were asked to micturate. The dose-rate mea-
surements were performed using a ceiling-mounted shielded
survey meter (automess–Automation und Messtechnik, Ger-
many) at a fixed distance of 2.5 m above the patient’s bed. The
patient measurements were carried out immediately after ad-
ministration and at least two times per day thereafter. The data
were normalized to the first initial measurement. In addition,
whole-body scans with a gamma camera (Symbia T2; Sie-
mens Healthcare, Germany) were performed 1 h and 24 h after
administration (medium energy collimator, energy window
208 keV ±10 %). In selected patients, an additional scan was
performed 4 h after treatment. The gamma camera whole-
body retention was calculated by normalizing the geometric
mean of subsequent background-corrected anterior and poste-
rior counts to the initial measurement. Both datasets were
combined to obtain the whole-body retention curve for each
patient.
Calculation of the time-integrated activity coefficients
and the absorbed doses
A biexponential fit function was adequate to determine the
function describing the activity as a function of time for the
whole body and blood. The time-integrated activity coeffi-
cients for the whole body and activity concentration in blood
(τtotal body(t) and τml of blood(t)) were calculated by integrating
the respective time–activity functions over time. Note the unit
of τtotal body is hours and the unit of τml of blood is hours per
millilitre because we considered only a small blood volume
(0.1 ml) for our measurements in the well counter. The
absorbed doses were calculated using a procedure analogous
to the EANM standard operational procedure for dosimetry in
the treatment of DTC [32] using the following equation:
Dblood tð Þ ¼ A0⋅ 85:3 Gy⋅ml
GBq⋅h






⋅τ total body tð Þ
 !
ð1Þ
where A0 is the administered activity and wt is the patient’s
weight in kilograms. The method is described inmore detail in
the Supplementary material.
Modelling the time-dependency of focus induction
and disappearance
Most in vitro and in vivo studies of ionizing radiation-induced
DSB formation have indicated a linear relationship between
the number of microscopically visible RIF and the absorbed
dose [15, 18, 27, 33], the dose–length product in CT exami-
nations [34, 35] or the total body dose in radiotherapy [36].
For our set-up and staining procedure we also observed a
linear dose–response relationship between the absorbed dose
to the blood and the number of RIF per cell in an in vitro
experiment [27].
As has been pointed out by Dale and Fowler [37], sublethal
DNA damage repairs monoexponentially, assuming that the
rate of repair at any instant is directly proportional to the
number of unrepaired lesions remaining (first-order process).
However, the same authors found that monoexponential repair
could not completely explain the observations made in several
clinical studies [37]. The easiest way to account for this would
be to introduce a multiexponential model with different repair
rates. Another model introduced by Fowler [38] and by Dale
et al. [39] assumes that the rate of repair of damaged lesions is
proportional to the square of their number (second-order pro-
cess); a finding, however, that has not been confirmed yet for
the DNA damage focus assay. Studies of the DNA damage
focus assay by Horn et al. [40] and Mariotti et al. [41] have
revealed that the number of RIF per cell decreases over time
with the onset of DNA repair, following a biexponential mod-
el [40, 41]. Hence, we decided to describe the decrease in the
number of RIF per cell over time with a biexponential model.
Therefore, the time dependency of the number of RIF per cell
as a function of the time-dependent absorbed dose and the
disappearance of foci can be described in the low absorbed
dose range by a linear dose-dependent increase using the input
of our in vitro calibration curve and biexponential decay
representing DNA repair:
N tð Þ ¼









N(t) is the number of foci at time t.
m is an adjustable parameter to account for the variability
in patient dosimetry with respect to the in vitro calibration
established by Eberlein et al. [27].
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a and b are constants describing the in vitro calibration
curve [27] representing the number of RIF per cell as a
function of the mean time-dependent absorbed dose D
blood(t) (a=0.0363 RIF/cell; b=0.00147 RIF/cell·mGy
-1).
D blood(t) is the mean absorbed dose to the blood (Eq. 1).
λ and υ are patient-specific adjustable parameters de-
scribing the decay rate of foci.
k is an adjustable parameter describing the fraction of
damage assigned to different repair rates. Since we per-
formed only two measurements at time-points >12 h, for
this study, we set k=1.
Statistics
Origin (version 9.1G+2015G, Origin Lab Corporation) was
used for data analysis and statistical evaluation. The normal
distribution of the datasets was tested using the Shapiro-Wilk
test. RIF per cell value data sets at different time-points were




Of 18 patients enrolled in the study, 16 were included (mean
age 61.2±10.5 years, Table 1). The patient demographics are
given in Table 1. Ten of the patients presented with NET.
Other diseases included adrenocortical cancer, meningioma
and papillary thyroid carcinoma. All patients except one pre-
sented with metastases. Thirteen patients were referred to our
centre because of progressive disease. The pretreatment of
these patients included surgery, chemotherapy, radiotherapy,
sandostatin, mitotane and everolimus. All pretreatment was
discontinued >1.5 months before PRRT.
For PRRT the patients received 177Lu-labelled DOTATA
TE (patients 1 – 11) or DOTATOC (patients 12 – 18) intrave-
nously (mean activity 7.2±0.4 GBq) via a perfusion system
over 20 min. Patients were then admitted to our ward and
discharged 2 days later. All blood samples and measurements
were taken during this time period. All patients responded
well to the treatment or showed disease stabilization at
follow-up and showed no therapy-related or study-related ad-
verse effects.
DNA damage foci
Peripheral blood lymphocytes were immunofluorescently
stained for γ-H2AX/53BP1 DNA damage foci and manually
counted for colocalizing DSB-marking foci. The average
numbers of RIF per cell were calculated subtracting the num-
ber of background foci for the different patient samples
(Fig. 1) as a function of time after administration of the radio-
pharmaceutical. The average number of RIF per cell increased
in the first hours after therapy, decreasing at later time-points
(Fig. 1, Table 2). The actual time-points differed slightly be-
cause of variations in management of individual patients. The
mean numbers of RIF per cell were 0.55 at 4 h, 0.42 at 24 h,
and 0.43 at 48 h after administration of 177Lu. Distribution
analysis of the numbers of RIF per cell identified the 48-h
value in patient Lu10 as an outlier that was excluded from
further analysis. All three datasets were distributed according
to a Gaussian distribution (Shapiro-Wilk test). Applying the
paired t test to all time-points revealed that there were statisti-
cally significant differences among the numbers of RIF per
cell at these different time-points (p<0.008) confirming the
observation that the number of RIF per cell decreased 5 h after
administration of the radiopharmaceutical.
Dosimetry
The absorbed doses to the blood in the individual patients
were calculated according to Eq. 1. The mean absorbed dose
was 34±13 mGy at 4 h, 63±15 mGy at 24 h and 79±16 mGy
at 48 h after administration (Table 2). The relative contribution
of the penetrating radiation to the absorbed dose 48 h after
treatment was less than 34 % in all patients. In the first few
hours after treatment the contribution was below 10 % (data
not shown). Due to the lack of data at time points>2 days, and
the associated uncertainty in extrapolating the data to time
infinity, the total absorbed dose was not calculated. The
absorbed dose to the blood increased steeply in the first few
hours after therapy (Fig. 2). In most patients, 50 % of the
absorbed dose to the blood at 48 h was reached within the first
5 h. In accordance with this observation, the dose-rate de-
creased until it was less than 0.5 mGy/h after 48 h. For com-
parison, Fig. 3 shows the average number of RIF per cell for
this example patient (Lu3) as a function of the absorbed dose
to the blood.
In vivo calibration of the DNA damage focus assay
The average numbers of RIF per cell as a function of the
absorbed dose in each patient for the first 5 h after treatment
are shown in Fig. 4. The first datasets up to 5 h after admin-
istration of the radiopharmaceutical were pooled. A linear fit
to our 177Lu patient data (in vivo calibration) resulted
in: y = 0.0321 + 0.0127·x, where y denotes the number of
RIF per cell and x the absorbed dose to the blood in milligray
(R2=0.72). The standard error of the y-axis intercept was
± 0.0152 RIF per cell and the standard error of the slope was
± 0.0009 RIF per cell·mGy−1. The y-axis intercept value in
this case takes the standard deviation of the background
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(maximum value± 0.09 RIF per cell) value into account.
Therefore, we did not force it to zero, although, no RIF per
cell would be expected at 0 mGy. For absorbed doses above
10 mGy the influence of the y-axis intercept on the number of
RIF per cell was less than 20 %. The resulting in vivo calibra-
tion curve for our 177Lu patient data including the 95 %
confidence interval is also shown in Fig. 4. In a previous study
we obtained an in vitro calibration curve for 131I and 177Lu
from blood samples of volunteers [27]. For comparison this
in vitro calibration curve is shown in Fig. 4. The relative
deviation of the slopes between the in vitro calibration curve
and the in vivo data is 14 %.















Lu1 65.8 96 7.03 DOTATOC NET, jejunum No Lymph nodes PD Surgery G1/2
Lu2 56.5 94 6.41 DOTATOC NET, pancreatic No Liver, bone PD CTx, everolimus G2







Lu4 67.9 82 6.60 DOTATOC Unknown primary No Bone, liver PD Sandostatin G2




PD Surgery, CTx –
Lu6 67.1 94 7.60 DOTATOC NET, lung No Lymph nodes,
pleura, bone
PD CTx >90 %
Lu7 56.4 41 7.00 DOTATOC Adrenocortical
cancer
Yes Lung, peritoneal PD Surgery, CTx,
mitotane
–
Lu8 30.6 95 7.30 DOTATOC NET, lung No Bone, liver,
lymph nodes
PD CTx, RTx –
Lu10 68.5 82 7.05 DOTATOC NET, ileum No Liver, lung,
lymph nodes
PD Sandostatin –
Lu11 67.2 70 7.13 DOTATOC NET, ileum No Liver, lymph
nodes
PD Surgery –
Lu12 61.5 70 7.70 DOTATATE Meningioma Yes – PD RTx –
Lu13 61.4 64 7.70 DOTATATE NET, pancreatic No Lymph nodes PT – G2
Lu14 48.8 60 7.54 DOTATATE NET, lung No Lymph nodes PT – 100 %
Lu16 67.5 79 7.01 DOTATATE Unknown primary No Liver PT – x





Lu18 72.2 67 6.99 DOTATATE NET, gastric No Liver PD Sandostatin G2
PD progressive disease, PT primary treatment, NET neuroendocrine tumour, CTx chemotherapy, RIT radioiodine therapy, RTx radiotherapy
a b
Fig. 1 Average RIF per cell as a function of time after administration of 177Lu: a all data, time-points 0 – 48 h; b detailed view of time-points 0 – 5 h
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Modelling
Individual fits of the patient data were performed according to
Eq. 2 using the datasets for the biokinetics of blood (λbl 1,2, Abl
1,2) and the total body (λtb 1,2 and Atb1,2) provided in Table S1
as well as the values of the in vitro calibration [27] (a and b).
Variable parameters to be fitted were m (adjustable parameter
to account for the variability in the patient dosimetry with
respect to the in vitro calibration) and the repair rate λ
(Table S1). For this study we chose k=1 in Eq. 2, thus describ-
ing the repair in terms of a monoexponential function only.
The reason was that we obtained only two blood samples per



















Lu1 0.03 27.1 0.56 44.4 0.27 53.6 19 0.20
Lu2 0.01 23.7 0.42 50.7 0.31 68.0 29 0.34
Lu3 0.06 42.0 0.49 63.6 0.39 76.8 16 0.29
Lu4 0.20 16.4 0.70 40.5 0.59 57.4 33 0.36
Lu5 0.02 45.1 0.38 85.2 0.23 110.4 11 0.11
Lu6 0.04 29.1 0.74 55.2 0.25 75.5 18 0.23
Lu7 0.03 58.9 0.65 86.4 0.37 95.5 7 0.38
Lu8 0.16 8.4 0.44 34.1 0.51 57.5 34 0.19
Lu10 0.05 36.5 0.92 65.7 0.57 85.0 18 0.82a
Lu11 0.33 39.3 0.63 67.7 0.52 80.2 16 0.28
Lu12 0.35 43.0 0.73 65.8 0.40 73.3 10 0.44
Lu13 0.40 36.3 0.32 64.9 0.36 77.3 15 0.28
Lu14 0.11 54.0 0.48 81.0 0.67 88.2 8 0.45
Lu16 0.39 40.7 0.31 76.6 - 84.7 9 0.32
Lu17 0.11 33.3 0.59 59.9 0.56 67.1 12 0.55
Lu18 0.10 22.0 0.47 68.6 0.23 106.5 22 0.21
Mean 0.15 34.7 0.55* 63.1 0.42* 78.6 17 0.34*




Fig. 2 Absorbed dose to the blood (a) and corresponding dose rate (b) in a selected patient (Lu3)
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patient at 24 h and 48 h after administration, which was not
sufficient for an adequate approximation of a biexponential
function. Because of the lack of late data points only a
monoexponential fit was possible; therefore, we could not
provide a second repair rate ν.
In general, the data followed the in vitro calibration curve
for the first 5 h after treatment. The mean value of the fitted
parameter m which accounts for the variability in patient do-
simetry with respect to the in vitro calibration was 1.28±0.66
(minimum 0.55, maximum 2.84). The mean decay rate (λ) in
all patients was 0.0379±0.0187 h−1 (minimum 0.014 h−1,
maximum 0.084 h−1) corresponding to 18.3 h effective decay
time. The maximum of this fitted curve including the average
parameters of all patients was at 7.2 h after administration of
177Lu. After 75.5 h the average number of RIF per cell
dropped below the maximum standard deviation of the base-
line value of 0±0.09 RIF per cell (Fig. 5). The standard devi-
ation of the background foci included the counting error.
Therefore, each data point was considered with appropriate
error propagation, even the baseline value of RIF per cell at
0 mGy.
Discussion
This study provides a first clear correlation between the aver-
age number of RIF per cell and the absorbed dose to the blood
after PRRT up to 5 h after administration of the β-emitter
177Lu. Absorbed doses to the blood of nearly all patients were
less than 100 mGy 48 h after treatment. Concomitant genera-
tion of a significantly elevated number of radiation-induced
DSB foci was noted up to 48 h after therapy (end of our
follow-up).
Recently, Denoyer et al. [31] analysed the kinetics of γ-
H2AX foci formation in peripheral blood lymphocytes of
11 patients undergoing PRRT. The number of γ-H2AX
foci in 50 – 100 cells per sample was determined before
and up to 72 h after treatment using a dedicated computa-
tional algorithm (TGIR foci-counting software) [42].
Denoyer et al. observed a variable response among pa-
tients, but, unlike our findings, detected no clear relation-
ship between the absorbed dose to the blood and the num-
ber of γ-H2AX foci. The correlations between γH2AX
foci yield and the absorbed doses presented by the authors
are poor or, in the case of bone marrow, lead to a negative
number of γ-H2Ax foci for bone marrow doses <100 mGy,
a fact which is neither explained nor discussed [42].
Fig. 3 Average RIF per cell as a function of the absorbed dose to the
blood in patient Lu3. The blood sampling times were: 0, 0.6, 1.1, 1.7, 2.3,
3.6, 24.1 and 44.7 h
Fig. 4 Average number of RIF per cell as a function of the absorbed dose
to the blood (over the first 5 h after 177Lu administration). The black line
is the linear fit to our 177Lu patient data (in vivo calibration curve)
including the 95 % confidence interval (CI), and the red line is the
in vitro calibration curve taken from Eberlein et al. [27] including the
95 % CI
Fig. 5 Average number of RIF per cell as a function of time after 177Lu
administration, including the modelled decay function using the mean
values of all foci–decay fits according to Eq. 2. Parameters are the
mean values presented in Table S1
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While there are many studies showing elevated foci levels
after exposure to ionizing radiation [33, 40, 43–48], only a
limited number of studies have shown the effects of the ther-
apeutic or diagnostic use of radionuclides [29–31, 35]. For
internal irradiation in molecular radiotherapy the time-course
of the induction and the number of RIF are different from
those following external irradiation, since after radionuclide
administration cells are irradiated not only for seconds or mi-
nutes, but are continuously irradiated over a longer period of
time with a permanently changing dose rate [29].
Blood-based dosimetry in PRRT using 177Lu shows several
differences from blood-based dosimetry of radioiodine as, for
example, described by Hänscheid et al. [49]. The absorbed dose
to the blood from the penetrating radiation of 177Lu is almost an
order magnitude lower than that from 131I. Therefore, the con-
tribution of penetrating radiation to the absorbed dose to the
blood is in most patients less than 20 % at 48 h after adminis-
tration of 177Lu, and even less in the first few hours after admin-
istration (data not shown). However, it is unknown how the
absorbed dose to the blood from penetrating radiation changes
due to uptake in the liver, spleen, tumour and metastases. The
mean observed absorbed dose to the blood after 48 h in the
177Lu-treated patients in this study was lower than the values
reported by Lassmann et al. [29] for 131I-treated thyroid carci-
noma patients. In agreement with Sandström et al. [50], this can
mainly be attributed to the fact that the activity in the blood has a
shorter half-life in the first hours after 177Lu administration than
after 131I administration. For clinical reasons, the blood sampling
times, particularly for the first samples, were variable and there-
fore, the first phase of the blood time–activity curve might not
have been a satisfying representation in all patients, a fact which
may have affected the correlation with the RIF induced in the
first few hours after administration of the radiopharmaceutical.
Overall, the absorbed doses to the blood were low in all
patients receiving 177Lu therapy, indicating that the likelihood
of haematological toxicity is rather low for this treatment, in
agreement with the findings of Sandström et al. in 200 patients
[50]. In a previous radioiodine DTC study we also
observed the decay in the average number of RIF per cell after
radioiodine therapy of DTC [29], with the highest number of
RIF per cell being observed 2 h after therapy; however, no
blood samples were available for the next few hours, while the
decrease of in the number of RIF per cell [29] at later time-
points mirrored the findings of the present study. Doai et al.
[30] observed no temporal dependency of γ-H2AX foci and
the absorbed dose to the blood, probably because their first
blood collection was at 96 h after radioiodine administration, a
time period that is, according to the current results and our
experience, too late to reveal a direct dose–response relation-
ship. May et al. [35] investigated the induction of γ-H2AX
foci by a PET tracer (18F-FDG) used in nuclear medicine
diagnostics. However, in that study the FDG PET (β-
exposure) was followed by exposure to X-rays fromCT. Thus,
the exposure to X-rays has likely obscured any RIF induced
by the radiopharmaceutical.
The observed numbers of RIF per cell for the first hours after
treatment obtained in this work are in good agreement with the
in vitro calibration curve [27] developed in our laboratory. The
slight differences in slope in relation to the in vitro calibration
curve can be explained by the results of two recent studies by
Hänscheid et al. [51, 52] in which the authors investigated the
absorbed doses to the blood from compounds that do not bind to
the blood. According to these results [51] the gamma component
is underestimated for 177Lu by a factor of about 2 as compared to
the model we assumed. In addition, when a realistic distribution
of vessel sizes is taken into account this results in a beta absorbed
dose that is lower than the maximum energy deposited by beta
particles [52]. A specific model for the case of PRRT describing
the absorbed dose to the blood is so far not available.
We are aware that the numbers of RIF per cell strongly
depend on the background values of the patients. As can be
seen in Table 2, these values underlie strong intrinsic varia-
tions, possibly related to age, lifestyle, nutrition, genetics
background and stress. Cell fixation as well as staining arte-
facts can also play a role in variability [48]; however, we
controlled for this by including internal 0 Gy and 1 Gy con-
trols in all staining reactions. Only staining reactions in which
control values were similar were evaluated. Other studies have
also shown a high variability in background values [29, 31,
46, 53, 54]. Overall, these findings show that the DNA dam-
age focus assaymay be used as an in vivo dosimeter in the first
hours after incorporation of beta-emitting radioisotopes.
The disappearance of RIF as a function of time has been
quantitatively investigated by Horn et al. [40] and by Mariotti
et al. [41], with the former describing the disappearance using
a biexponential decay function with a short decay rate of
0.350 h−1 (77 %) and a longer-lived component of 0.018 h−1
(23 %). Mariotti et al. also described, for a single acute
absorbed dose of 1 Gy, biexponential decay with a short com-
ponent (relative contribution 91 %, decay constant 0.23 h−1)
and a second phase that showed almost no decay (relative
contribution 9 %, 3.32 × 10−12 h−1). In the current study, for
logistic reasons, we were only able to include two blood sam-
ples per patient obtained >5 h after administration of 177Lu.
Hence, we decided to describe the decay using a
monoexponential function only. Our RIF per cell decay rates
lie, with one exception (patient Lu14: 0.014 h−1), within the
range of values reported by Horn et al. [40]. The value for
patient Lu14 could potentially be interpreted as showing a
lower repair rate of DNA damage than in the other patients;
however, this finding could also be explained by the variabil-
ity in the individual patient dosimetry data. In patients with a
very low repair rate (patients Lu14 and Lu16) or a very high
repair rate (patients Lu6 and Lu18), no obvious link between
these findings the condition of the patients, and the pretreat-
ments or stage of disease could be found.
1746 Eur J Nucl Med Mol Imaging (2015) 42:1739–1749
Further studies with more patients and different tracer ki-
netics in the blood are needed to better identify patients with
deviating repair rates.
Conclusion
This study shows the effect of ionizing radiation on blood
lymphocytes after systemic administration of a radiopharma-
ceutical in the course of PRRT as a function of the absorbed
dose to the blood. For the first time a clear correlation between
the average number of RIF per cell and the absorbed dose to
the blood up to 5 h after 177Lu administration has been
established. In the first hours after 177Lu administration, the
average number of RIF per cell closely followed our in vitro
calibration curve, thereby enabling the use of the DNA focus
damage assay as an in vivo dosimeter. At 24 h and 48 h after
177Lu administration the mean number of RIF decreased, in
accordance with the progression of DNA repair and declining
dose rates.
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